Washington, July 17, 2014 – Deloitte announced today that Terri Cooper, Ph.D., has been selected to lead its Federal Health sector. Dr. Cooper, a principal in Deloitte Consulting LLP, also serves as the lead client service partner for the National Institutes of Health (NIH). Deloitte’s Federal Health practice serves clients across three cabinet level agencies (Department of Health and Human Services, Veterans Affairs and Department of Defense’s Military Health System). With the support of over 1,500 practitioners Deloitte provides extensive services spanning mission critical operations, enterprise-wide initiatives, as well as key operation’s needs.
Prior to taking on the Federal Health sector role, Dr. Cooper was the national leader of the Deloitte Life Sciences Research and Development (R&D) practice. Throughout her 20-plus-year career working in the Healthcare Life Sciences industry she has participated in a broad range of strategic advisory services including restructuring all aspects of the R&D value chain and driving increased cost and efficiency measures.
“We are very pleased to welcome Terri to her new role as Deloitte Health sector leader,” said Janet Foutty, principal, Deloitte Consulting LLP and Federal Practice leader. “With deep experience in the life sciences industry, her background is a tremendous asset for Deloitte’s Federal Health clients as they look to develop new and innovative operating models and improve outcomes and efficiency.”
Dr. Cooper succeeds Kelvin Womack, principal, Deloitte Consulting LLP, who will continue in client leadership roles within Deloitte’s provider sector practice. Deloitte’s provider practice advises hospital systems, clinics and physician practices in the U.S. health industry as it shifts from a volume to a value-based payment system. Womack will also continue his work as the national managing principal for Diversity and will take on a leadership role at Deloitte University designing future leadership curricula for Deloitte partners, principals and directors.
Dr. Cooper’s prior work experience includes eight years within the pharmaceutical industry. Her background spanned basic research, clinical development, regulatory affairs, sales, and marketing including the development of new products and obtaining product licenses in the U.K. and the U.S. She also contributed to the launch of a major new pharmaceutical brand while also maintaining the growth of older existing products in the competitive therapeutics industry.
Dr. Cooper also serves as the national chief inclusion leader for Deloitte Consulting LLP with responsibility for the practice’s Women’s Initiative (WIN), diversity and flexibility initiatives. She holds a Joint Honors Bachelor of Science degree in chemistry and pharmacology, and a doctorate in pharmacology from the University of London, U.K.
About Deloitte’s Federal Government practice
More than 6,600 Deloitte professionals are dedicated to serving U.S. federal clients with wide-ranging missions. Deloitte is helping federal organizations explore how to be more efficient or seize the opportunity to do things differently, with a deep understanding of the government’s requirements, processes and systems along with insights into workforce and technology issues. Deloitte applies a mix of private-sector insights and public-sector experience to help federal agencies rethink, reduce, and restructure – from day-to-day operations to large-scale transformations. To learn more, visit www.deloitte.com/federal.
As used in this document, “Deloitte” means Deloitte LLP and its subsidiaries. Please see www.deloitte.com/us/about for a detailed description of the legal structure of Deloitte LLP and its subsidiaries. Certain services may not be available to attest clients under the rules and regulations of public accounting.